Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Update

Allarity Therapeutics, Inc. (NASDAQ:ALLR) was the target of a significant decline in short interest in January. As of January 30th, there was short interest totaling 215,761 shares, a decline of 14.7% from the January 15th total of 253,018 shares. Based on an average daily trading volume, of 129,627 shares, the days-to-cover ratio is currently 1.7 days. Approximately 1.3% of the company’s stock are sold short. Approximately 1.3% of the company’s stock are sold short. Based on an average daily trading volume, of 129,627 shares, the days-to-cover ratio is currently 1.7 days.

Wall Street Analysts Forecast Growth

ALLR has been the topic of a number of recent analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Allarity Therapeutics in a research report on Wednesday, January 21st. Ascendiant Capital Markets increased their target price on Allarity Therapeutics from $9.25 to $9.50 and gave the company a “buy” rating in a report on Tuesday, December 9th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $9.50.

Allarity Therapeutics Price Performance

Shares of ALLR opened at $0.90 on Thursday. Allarity Therapeutics has a 1-year low of $0.61 and a 1-year high of $2.35. The stock has a market cap of $14.50 million, a PE ratio of -1.53 and a beta of 0.24. The firm has a fifty day moving average price of $1.05 and a 200 day moving average price of $1.25.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ALLR. Jane Street Group LLC purchased a new stake in Allarity Therapeutics in the second quarter valued at approximately $27,000. XTX Topco Ltd purchased a new stake in Allarity Therapeutics in the 4th quarter valued at $36,000. Geode Capital Management LLC boosted its stake in Allarity Therapeutics by 49.3% during the 2nd quarter. Geode Capital Management LLC now owns 50,650 shares of the company’s stock worth $51,000 after purchasing an additional 16,729 shares during the period. Capital Advisors Inc. OK purchased a new position in Allarity Therapeutics during the 4th quarter worth $108,000. Finally, DRW Securities LLC acquired a new position in Allarity Therapeutics in the fourth quarter valued at $133,000. Hedge funds and other institutional investors own 11.53% of the company’s stock.

Allarity Therapeutics Company Profile

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.